Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1

Bai, Zhigang; Zhang, Zhongtao; Qiu, Xiang; Han, Wei; Ma, Xuemei

doi:10.3892/ol.2011.416

Cited by 16 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lih et al 7 have demonstrated that increase in TXR1 and decrease in TSP1 expression was highly correlated with taxane resistance in cancer cells. Bai et al 16 showed that TXR1 expression was associated with a resistant phenotype of breast cancer cells in vitro. However, it remains unknown whether TXR1 and TSP1 expression correlates with the outcome of breast cancer patients who receive taxane-based chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

TXR1 and TSP1 expression varies by the molecular subtypes of breast cancer patients who received previous docetaxel-based first-line chemotherapy

Zhang

Qiu

et al. 2016

Exp Biol Med (Maywood)

Self Cite

View full text Add to dashboard Cite

The expression of taxol resistance gene 1 and thrombospondin 1 remains unknown in human breast cancer tissues. In the current study, we sought to measure the mRNA expression levels of taxol resistance gene 1 and thrombospondin 1 in breast cancer tissue and adjacent normal tissue specimens and further analyzed their expression according to the molecular subtypes and age of breast cancer patients who had received taxane-containing regimens. Archived breast cancer and adjacent non-tumor tissue specimens were obtained at Beijing Friendship Hospital, Beijing, China. The mRNA transcript levels of taxol resistance gene 1, thrombospondin 1 and multi-drug resistance 1 were determined by quantitative RT-PCR. Taxol resistance gene 1 and multi-drug resistance 1 protein levels were measured by immunoblotting assays. Forty-nine archived breast cancer tissue specimens were included. The majority of the specimens (65.3%) were of the molecular subtype A followed by triple negative breast cancer (14.3%). The mRNA transcript levels of taxol resistance gene 1 , thrombospondin 1 and multi-drug resistance 1 in breast cancer tissues were higher than those of adjacent normal tissues. The mRNA expression of TXR1 in the HER2 subtype (4.513 AE 0.810) was the highest and in the Luminal B subtype was the lowest (3.103 AE 0.417) among the four molecular subtypes. The HER2 subtype also had the highest mRNA expression of thrombospondin 1(4.827 AE 0.927) and the Luminal B subtype had the lowest TSP1 mRNA level (3.197 AE 0.565) among the four molecular subtypes. Our study represents the first attempt in delineating taxol resistance gene 1 and thrombospondin 1 expression in breast cancer and we demonstrate that taxol resistance gene 1 and thrombospondin 1 expression may vary according to the molecular subtypes of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Papadaki et al 15 also demonstrated that low TXR1 and high TSP1 expression was an independent factor for increased PFS docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. In breast cancer MCF-7 cells, Bai et al 16 showed that increased expression of TXR1 was associated with a taxol-resistant phenotype.…”

mentioning

confidence: 99%

TXR1 and TSP1 expression varies by the molecular subtypes of breast cancer patients who received previous docetaxel-based first-line chemotherapy

Zhang

Qiu

et al. 2016

Exp Biol Med (Maywood)

Self Cite

View full text Add to dashboard Cite

show abstract

“…SiRNAs are a class of small synthetic double-stranded RNAs which can induce gene silencing through sequence-specific cleavage of perfectly complementary mRNA [ 86 ]. In the last decades, the potential of siRNA-based therapy in cancer treatment has determined a huge concentration of studies and led to promising results on the inhibition of cancer cell growth and migration and the enhancement of drug response [ 87 , 88 , 89 , 90 , 91 , 92 ]. Recently, many investigators have focused their efforts on the use of siRNA-based therapy to reprogram the TME and alter the crosstalk between stromal and cancer cells [ 93 , 94 , 95 , 96 , 97 , 98 ] ( Table 3 ).…”

Section: Synthetic Rna-based Therapeutic Approaches For Caf Targetmentioning

confidence: 99%

Emerging Therapeutic RNAs for the Targeting of Cancer Associated Fibroblasts

Santana-Viera

Ibba

Rotoli

et al. 2020

Cancers

View full text Add to dashboard Cite

Tumor mass consists of a complex ensemble of malignant cancer cells and a wide variety of resident and infiltrating cells, secreted factors, and extracellular matrix proteins that are referred as tumor microenvironment (TME). Cancer associated fibroblasts (CAFs) are key TME components that support tumor growth, generating a physical barrier against drugs and immune infiltration, and contributing to regulate malignant progression. Thus, it is largely accepted that therapeutic approaches aimed at hampering the interactions between tumor cells and CAFs can enhance the effectiveness of anti-cancer treatments. In this view, nucleic acid therapeutics have emerged as promising molecules. Here, we summarize recent knowledge about their role in the regulation of CAF transformation and tumor-promoting functions, highlighting their therapeutic utility and challenges.

show abstract

“…Txr1 is a drug resistance gene receiving increasing attention; this gene decreases thrombospondin-1 (TSP1) secretion and causes taxol resistance ( 8 ). Previous studies using lung ( 9 ) and breast ( 10 ) cancer cells have revealed that Txr1 upregulation may induce drug resistance in cancer cells. Our previous study revealed that Txr1 expression is also associated with the 5-year overall survival (OS) rate of GC patients and may represent a target to reverse L-OHP resistance in GC ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin

Liu

Bai

et al. 2016

Experimental and Therapeutic Medicine

Self Cite

View full text Add to dashboard Cite

The present study aimed to evaluate the role of taxol resistance gene 1 (Txr1) in the development of oxaliplatin (L-OHP) resistance in gastric cancer (GC). Using SGC-7901 cells as a model, Txr1 was exogenously expressed or knocked down using small interfering RNA. Quantitative polymerase chain reaction (qPCR) and western blotting were performed to establish whether the Txr1 gene is involved in chemoresistance, and cell proliferation was assessed using an MTS assay. To this end, the mRNA and protein levels of Txr1, thrombospondin-1 and excision repair cross-complementing 1 protein were measured using qPCR and western blotting, respectively. Txr1-knockdown significantly increased the sensitivity of the SGC-7901 cells to L-OHP, whereas Txr1 overexpression promoted the resistance of the SGC-7901 cells to L-OHP. Exogenous Txr1 expression in the SGC-7901 cells induced L-OHP resistance, and the siRNA knockdown of Txr1 sensitized the human GC cells to L-OHP. Txr1 is, therefore, likely to play a role in L-OHP resistance, acting via TSP1, and should be investigated as a potential therapeutic target in the treatment of GC.

show abstract

Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1

Cited by 16 publications

References 21 publications

TXR1 and TSP1 expression varies by the molecular subtypes of breast cancer patients who received previous docetaxel-based first-line chemotherapy

TXR1 and TSP1 expression varies by the molecular subtypes of breast cancer patients who received previous docetaxel-based first-line chemotherapy

Emerging Therapeutic RNAs for the Targeting of Cancer Associated Fibroblasts

Effects of taxol resistance gene 1 expression on the chemosensitivity of SGC-7901 cells to oxaliplatin

Contact Info

Product

Resources

About